PHRX (Pharmagen) Notes Receivable: $0.00 Mil (As of Mar. 2014)


What is Pharmagen Notes Receivable?

Pharmagen PHRX -90.00% Notes Receivable is $0.00 Mil as of Mar. 2014.

Pharmagen's Notes Receivable for the quarter that ended in Mar. 2014 was $0.00 Mil.

Pharmagen Notes Receivable Historical Data

* Premium members only.

The historical data trend for Pharmagen's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmagen Notes Receivable Chart

Pharmagen Annual Data
Trend Jun10 Jun11 Dec12 Dec13
Notes Receivable
0.00 0.00 0.00 0.00

Pharmagen Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharmagen Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Pharmagen (PHRX) has a Notes Receivable of $0.00 Mil as of Mar. 2014. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Pharmagen and its competitors.
Is Pharmagen's Notes Receivable too high?
Pharmagen's current Notes Receivable is $0.00 Mil.
How does Pharmagen's Notes Receivable compare to FZMD and SNYR?
Pharmagen's Notes Receivable of $0.00 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Distribution company?
A good Notes Receivable depends on the Medical Distribution industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Pharmagen and its competitors. Pharmagen's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagen stock overvalued right now?
Pharmagen (PHRX) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Pharmagen (PHRX), the current Notes Receivable is $0.00 Mil as of Mar. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagen Business Description

Address 9337 Fraser Avenue, Silver Spring, MD, USA, 20910
Pharmagen Inc as a distributor of specialty drugs, compounding and admix pharmacy, and producer of over-the-counter branded multivitamins to the healthcare provider market. The company distributes hard-to-find and specialty drugs to the healthcare provider market throughout the United States, while functioning as an aggregator of real-time market demand for these products.